Summit Therapeutics Inc.
SMMT
Hisse Senetlerindeki Sıralama
#1684
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Hisse Fiyatı
$15.80
Son senkronizasyon: 2026-10-21
Piyasa Değeri
$12.61B
Değişim (1 gün)
-1.78%
Değişim (1 yıl)
-17.52%
Ülke
US
Ticaret Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Summit Therapeutics Inc. (SMMT) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $16.40 - 2026-10-01
Gün sonu en düşük fiyat: $11.32 - 2015-03-01
Gün sonu en düşük fiyat: $11.32 - 2015-03-01
Summit Therapeutics Inc. için hisse fiyatı geçmişi: 2015 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | -6.35% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
